Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Carboplatin and Paclitaxel for Adenocarcinoma of Unknown Primary
NCT00201734Phase 2Terminated
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jun 2005
- Primary completion
- Nov 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in Adenocarcinoma, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Maximum Tolerated Dose at 24 weeks and Objective Response Rate at 24 weeks. Started Jun 2005; status: terminated.
02
Drugs
capecitabine
03
Conditions
Adenocarcinoma
Beyond the preview
Go deeper on NCT00201734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201734.